Pfizer, Inc. (PFE) Position Maintained by Taylor Cottrill Erickson & Associates Inc.

Taylor Cottrill Erickson & Associates Inc. held its position in shares of Pfizer, Inc. (NYSE:PFE) during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 46,691 shares of the biopharmaceutical company’s stock at the close of the 2nd quarter. Taylor Cottrill Erickson & Associates Inc.’s holdings in Pfizer were worth $1,568,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also added to or reduced their stakes in the stock. Harbour Capital Advisors LLC grew its position in shares of Pfizer by 3,056.2% during the second quarter. Harbour Capital Advisors LLC now owns 418,296 shares of the biopharmaceutical company’s stock worth $12,453,000 after purchasing an additional 405,043 shares in the last quarter. First Merchants Corp grew its position in shares of Pfizer by 7.5% during the second quarter. First Merchants Corp now owns 78,613 shares of the biopharmaceutical company’s stock worth $2,640,000 after purchasing an additional 5,466 shares in the last quarter. IBM Retirement Fund grew its position in shares of Pfizer by 70.2% during the second quarter. IBM Retirement Fund now owns 144,828 shares of the biopharmaceutical company’s stock worth $5,436,000 after purchasing an additional 59,732 shares in the last quarter. NGAM Advisors L.P. grew its position in shares of Pfizer by 3.8% during the second quarter. NGAM Advisors L.P. now owns 1,381,782 shares of the biopharmaceutical company’s stock worth $46,414,000 after purchasing an additional 49,992 shares in the last quarter. Finally, Sumitomo Life Insurance Co. grew its position in shares of Pfizer by 4.4% during the second quarter. Sumitomo Life Insurance Co. now owns 188,699 shares of the biopharmaceutical company’s stock worth $6,338,000 after purchasing an additional 8,000 shares in the last quarter. Hedge funds and other institutional investors own 68.98% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: This article was first reported by Markets Daily and is the sole property of of Markets Daily. If you are viewing this article on another website, it was stolen and reposted in violation of United States and international trademark and copyright laws. The correct version of this article can be accessed at https://www.themarketsdaily.com/2017/10/18/pfizer-inc-pfe-position-maintained-by-taylor-cottrill-erickson-associates-inc.html.

Several analysts recently issued reports on the company. Jefferies Group LLC set a $35.00 target price on Pfizer and gave the stock a “neutral” rating in a research report on Wednesday, August 2nd. Berenberg Bank set a $39.00 target price on Pfizer and gave the stock a “neutral” rating in a research report on Tuesday, August 1st. Zacks Investment Research upgraded Pfizer from a “hold” rating to a “buy” rating and set a $40.00 target price for the company in a research report on Tuesday, October 3rd. Cowen and Company set a $43.00 target price on Pfizer and gave the stock a “buy” rating in a research report on Monday, August 14th. Finally, Vetr cut Pfizer from a “buy” rating to a “hold” rating and set a $35.71 target price for the company. in a research report on Wednesday, September 13th. Two equities research analysts have rated the stock with a sell rating, nine have issued a hold rating and twelve have assigned a buy rating to the stock. The stock has a consensus rating of “Hold” and a consensus target price of $38.15.

In other news, insider Laurie J. Olson sold 8,064 shares of the company’s stock in a transaction that occurred on Monday, August 21st. The stock was sold at an average price of $32.70, for a total value of $263,692.80. Following the completion of the sale, the insider now directly owns 74,506 shares in the company, valued at $2,436,346.20. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Sally Susman sold 38,230 shares of the company’s stock in a transaction that occurred on Tuesday, September 12th. The shares were sold at an average price of $35.00, for a total value of $1,338,050.00. Following the completion of the sale, the insider now owns 145,649 shares of the company’s stock, valued at $5,097,715. The disclosure for this sale can be found here. Insiders sold 464,521 shares of company stock valued at $15,813,961 over the last 90 days. Company insiders own 0.06% of the company’s stock.

Pfizer, Inc. (NYSE PFE) opened at 36.20 on Wednesday. The stock has a market cap of $215.29 billion, a PE ratio of 26.48 and a beta of 1.00. The stock has a 50 day moving average price of $35.25 and a 200-day moving average price of $33.76. Pfizer, Inc. has a one year low of $29.83 and a one year high of $36.60.

Pfizer (NYSE:PFE) last posted its quarterly earnings results on Tuesday, August 1st. The biopharmaceutical company reported $0.67 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.65 by $0.02. The business had revenue of $12.90 billion during the quarter, compared to analyst estimates of $13.08 billion. Pfizer had a return on equity of 24.51% and a net margin of 15.84%. The business’s revenue was down 1.9% compared to the same quarter last year. During the same period in the prior year, the business earned $0.64 earnings per share. Equities research analysts expect that Pfizer, Inc. will post $2.56 earnings per share for the current fiscal year.

The business also recently declared a quarterly dividend, which will be paid on Friday, December 1st. Stockholders of record on Friday, November 10th will be given a $0.32 dividend. The ex-dividend date of this dividend is Thursday, November 9th. This represents a $1.28 dividend on an annualized basis and a dividend yield of 3.54%. Pfizer’s dividend payout ratio (DPR) is presently 94.12%.

Pfizer Company Profile

Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer, Inc. (NYSE:PFE).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply